Longitudinal evolution of O-(2-[18F]-fluoroethyl)-L-tyrosine PET metrics in serial imaging during glioblastoma progression.
BACKGROUND: Most studies evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET for glioblastoma progression rely on single-scan assessments, leaving diagnostic uncertainties in cases with borderline tracer uptake. We evaluated metabolic activity evolution during the transition of glioblastoma progression using serial FET PET to determine whether longitudinal parameter changes improve diagnostic certainty. PATIENTS AND METHODS: Between 2016 and 2026, 182 patients with glioblastoma undergoing 690 dynamic FET PET scans (median, 3; range, 2-12) were retrospectively evaluated. Eligible cases required documented progressive disease according to RANO 2.0 criteria and serial FET PET at least 2 time points (at suspected progression and within a 6-month prior window). Static PET parameters, ie tumor-to-brain ratios (TBRmean, TBRmax) and metabolic tumor volume (MTV), and their longitudinal changes were evaluated according to PET RANO 1.0 criteria, alongside additional dynamic PET parameters (time-to-peak). Single-scan metrics and serial changes were compared in cases with borderline uptake. RESULTS: Ninety patients with 102 confirmed progression events met all selection criteria (median interscan interval, 2.7 months). At progression, TBRmean, TBRmax, and MTV increased significantly (P < .001). Median percentage increases were modest for TBRmean (+4%) and TBRmax (+17%), whereas MTV exhibited a substantial expansion (+182%). In cases with borderline uptake, applying a longitudinal MTV increase criterion of ≥40% per PET RANO 1.0 substantially improved progression detection to up to 89%, yielding a 14% higher diagnostic detection rate compared to single-scan thresholds. CONCLUSIONS: In glioblastomas with documented RANO 2.0 progression, integrating longitudinal MTV changes markedly improves diagnostic certainty over single-scan uptake metrics, particularly in challenging cases with borderline uptake.
Authors
- Gereon R. Fink (ORCID: https://orcid.org/0000-0002-8230-1856)
- Isabelle Stetter (ORCID: https://orcid.org/0009-0007-1732-5759)
- Norbert Galldiks (ORCID: https://orcid.org/0000-0002-2485-1796)
- Karl‐Josef Langen (ORCID: https://orcid.org/0000-0003-1101-5075)
- Jurij Rosen (ORCID: https://orcid.org/0000-0003-4606-1602)
- Jan‐Michael Werner (ORCID: https://orcid.org/0000-0001-7147-4594)
- Mirko Kraft
- Julia Hilgers
- Philipp Lohmann (ORCID: https://orcid.org/0000-0002-5360-046X)
- Keith George Ciantar (ORCID: https://orcid.org/0000-0002-6467-726X)
- Jana-Marie Peplinski
- Chistian Filss
- Gabriele Stoffels
Institutions
- Forschungszentrum Jülich (DE)
- University of Cologne (DE)
- Universitätsklinikum Aachen (DE)
- University Hospital Cologne (DE)
- RWTH Aachen University (DE)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1093/neuonc/noag265
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00